Abstract
Background: In HER2+ breast cancer (BC) patients undergoing neoadjuvant treatment (NAT), higher levels of baseline TILs are associated with both increased rates of pathologic complete response (pCR) and improved survival. Data regarding the prognostic role of TILs on residual disease (RD) in patients failing to achieve pCR are conflicting.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have